Picture of Elicio Therapeutics logo

ELTX — Elicio Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareMicro CapSucker Stock

Elicio Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

* Elicio Therapeutics Inc  ELTX.OQ  reported a quarterly
adjusted
loss of 64 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of $-2.44.  The mean expectation of two analysts
for the quarter was for a loss of 96 cents per share. Wall
Street expected results to range from $-1.04 to -88 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Elicio Therapeutics Inc's reported EPS for the quarter was
a
loss of 64 cents​.
    * The company reported a quarterly loss of $7.23 million.
    * Elicio Therapeutics Inc shares had risen by 5.1% this
quarter and lost 48.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "hold."

Wall Street's median 12-month price target for Elicio
Therapeutics Inc is $10.00 
This summary was machine generated from LSEG data August 13 at
09:49 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jan. 1 0001       -0.96          -0.64          Beat
 Mar. 31 2024      -1.09          -1.15          Missed
 Dec. 31 2023      -0.78          -1.75          Missed
 Sep. 30 2023      -0.80          -1.27          Missed

Recent news on Elicio Therapeutics

See all news